BIO 2015 Dispatches: Acorda CEO Cohen To Bring 'Passion' To BIO Chairmanship
This article was originally published in The Pink Sheet Daily
Executive Summary
Congenial Acorda CEO Ron Cohen is chosen to lead the industry group during the upcoming year as the biotech industry gathers in Philadelphia for BIO's annual conference.
You may also be interested in...
Ampyra Approval: Acorda's Lessons Learned
There are many factors that contributed to Acorda's success in gaining approval for Ampyra (dalfampridine), but looking back at the process, CEO Ron Cohen and Chief Scientific Officer Andy Blight agree that the biggest asset was having a Special Protocol Assessment for the Phase III trials.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.